The Medicines (MDCO) Receives Daily News Sentiment Score of 0.14
Headlines about The Medicines (NASDAQ:MDCO) have trended somewhat positive recently, according to Accern. Accern identifies negative and positive news coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. The Medicines earned a news sentiment score of 0.14 on Accern’s scale. Accern also assigned headlines about the company an impact score of 45.8367751411421 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.
These are some of the news headlines that may have effected Accern’s scoring:
- BRIEF-Janssen seeks expanded use of Darzalex from EMA (feeds.reuters.com)
- NeuroVive Pharmaceutical AB Interim Report January – September 2017 (prnewswire.com)
- EU drugs agency move to Amsterdam minimises likely staff losses (feeds.reuters.com)
- The Medicines Target of Unusually High Options Trading (MDCO) (americanbankingnews.com)
- The Medicines Company Names Dr. Fred Eshelman as Executive Chairman; Appoints Geno Germano to Its Board of … – Business Wire (press release) (businesswire.com)
A number of research analysts have recently commented on MDCO shares. Chardan Capital reaffirmed a “buy” rating and set a $85.00 target price (up previously from $80.00) on shares of The Medicines in a research note on Tuesday, August 29th. Zacks Investment Research lowered The Medicines from a “hold” rating to a “strong sell” rating in a report on Tuesday, October 10th. Guggenheim assumed coverage on The Medicines in a report on Monday, October 23rd. They issued a “buy” rating and a $45.00 price target for the company. Jefferies Group LLC reiterated a “buy” rating and issued a $54.00 price target on shares of The Medicines in a report on Thursday, September 14th. Finally, Oppenheimer Holdings, Inc. set a $50.00 target price on The Medicines and gave the stock a “hold” rating in a report on Wednesday, October 4th. Two equities research analysts have rated the stock with a sell rating, two have issued a hold rating and seven have issued a buy rating to the company. The stock has an average rating of “Hold” and a consensus price target of $53.67.
Shares of The Medicines (MDCO) traded down $0.02 on Tuesday, hitting $31.18. The stock had a trading volume of 937,092 shares, compared to its average volume of 1,431,432. The Medicines has a 12-month low of $28.00 and a 12-month high of $55.95. The company has a quick ratio of 1.79, a current ratio of 2.31 and a debt-to-equity ratio of 3.42.
The Medicines (NASDAQ:MDCO) last issued its quarterly earnings data on Wednesday, October 25th. The company reported ($0.42) EPS for the quarter, beating the consensus estimate of ($1.37) by $0.95. The Medicines had a negative return on equity of 174.68% and a negative net margin of 767.94%. The firm had revenue of $16.87 million during the quarter, compared to analyst estimates of $26.06 million. During the same quarter in the prior year, the business posted ($0.64) EPS. The business’s revenue for the quarter was down 55.1% compared to the same quarter last year. analysts forecast that The Medicines will post -8.84 earnings per share for the current year.
About The Medicines
The Medicines Company is a global biopharmaceutical company. The Company is focused on advancing the treatment of acute and intensive care patients through the delivery of medicines to the hospital marketplace around the world. It markets Angiomax (bivalirudin), Ionsys (fentanyl iontophoretic transdermal system), Minocin (minocycline) for injection and Orbactiv (oritavancin).
Receive News & Stock Ratings for The Medicines Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for The Medicines Company and related stocks with our FREE daily email newsletter.